NASH and Systemic Complications From Basic to Clinical Research

Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress...

Full description

Saved in:
Bibliographic Details
Other Authors: Shiri-Sverdlov, Ronit (Editor), Baumgartner, Sabine (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_78818
005 20220224
003 oapen
006 m o d
007 cr|mn|---annan
008 20220224s2022 xx |||||o ||| 0|eng d
020 |a books978-3-0365-2979-0 
020 |a 9783036529790 
020 |a 9783036529783 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-2979-0  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a GP  |2 bicssc 
100 1 |a Shiri-Sverdlov, Ronit  |4 edt 
700 1 |a Baumgartner, Sabine  |4 edt 
700 1 |a Shiri-Sverdlov, Ronit  |4 oth 
700 1 |a Baumgartner, Sabine  |4 oth 
245 1 0 |a NASH and Systemic Complications  |b From Basic to Clinical Research 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (232 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress to fibrosis and cirrhosis, which may eventually lead to liver failure and death. While we have increased our mechanistic knowledge regarding the pathogenesis of NASH within the last decade, treatment options are still limited and liver biopsies have remained the gold standard for diagnosis. To achieve major clinical breakthroughs for NASH patients, it is not sufficient to use a single animal model, since each model has specific limitations. Furthermore, we should rely more on alternative models such as organ-on-a-chip, which will enable us to explore unknown aspects of disease pathogenesis much faster and serve as clinically relevant surrogates for murine models. Another important direction for the improvement of patient health is to pay more attention to extrahepatic, organ-specific and systemic effects, which are associated with NASH. The articles in this Special Issue include an up-to-date overview of the rapidly developing technologies, novel targets for intervention and insights in the field in NASH. Additionally, these articles describe the major challenges in the field, strategies to overcome them and suggestions for future directions. To improve patient's outcome, clinicians, as well as scientists with biomedical, nutrition, physics and mathematics backgrounds, should join forces. Although challenges remain, the future of the field seems promising as these novel technologies and developments are expected to lead to progress in NASH. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
653 |a NAFLD 
653 |a mouse models 
653 |a multifactorial disease 
653 |a translational value 
653 |a non-alcoholic fatty liver disease 
653 |a steatohepatitis 
653 |a NASH 
653 |a cognitive impairment 
653 |a memory dysfunction 
653 |a Alzheimer's disease 
653 |a neurodegeneration 
653 |a liver stiffness 
653 |a liver steatosis 
653 |a controlled attenuation parameter 
653 |a transient elastography 
653 |a MRI PDFF 
653 |a MR spectroscopy 
653 |a non-alcoholic steatohepatitis (NASH) 
653 |a tunneling nanotubes (TNTs) 
653 |a primary hepatocytes 
653 |a organelle transfer 
653 |a mesenchymal stromal cells 
653 |a aminopyrine 
653 |a microsomal 
653 |a liver function 
653 |a breath test 
653 |a nonalcoholic fatty liver disease 
653 |a nonalcoholic steatohepatitis 
653 |a extracellular vesicles 
653 |a magnesium (Mg2+) 
653 |a obesity 
653 |a insulin resistance (IR) 
653 |a type 2 diabetes mellitus (T2DM) 
653 |a hypertension 
653 |a cardiovascular diseases (CVD) 
653 |a non-alcoholic steatohepatitis 
653 |a intestinal permeability 
653 |a microbiota 
653 |a probiotics 
653 |a physical exercise 
653 |a fecal microbiota transplantation 
653 |a hepatocellular carcinoma 
653 |a pathogenesis 
653 |a extra-hepatic outcome 
653 |a organ-on-a-chip 
653 |a artificial intelligence 
653 |a liver disease 
653 |a GLP-1 agonist 
653 |a SGLT-2 inhibitor 
653 |a type 2 diabetes 
653 |a innate immune system 
653 |a adaptive immune system 
653 |a metabolic syndrome 
653 |a fatty liver 
653 |a leptin 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/4913  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/78818  |7 0  |z DOAB: description of the publication